// App-Quantinova.ai

: Real world prospective evaluation of clinical outcomes in patients with non-metastatic castrate resistant prostate cancer treated with darolutamide.

Researchers

Presenter

  • Amarnath Challapalli

Principal Investigators

  • Emily Renninson

  • Paul White

  • Thiraviyam Elumalai

  • Omi Parikh

  • Alexander Vickers

  • Alison Jane Birtle

  • Andrew Brocklehurst

  • Rajanee Bhana

  • Kanchana Wickramasinghe

  • Kamalram Thippu Jayaprakash

  • Emma Gray

  • Matthew Sephton

  • Anna Bowzyk Al-Naeeb

  • Emily Foulstone

  • Alexandra Soundy

  • Lauren Ashurst

  • Amit Bahl

Medical Centers

  • The Christie Hospital, Manchester, United Kingdom

  • Queen Elizabeth Hospital Kings Lynn, Kings Lynn, United Kingdom

  • Microbiology - Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom

  • University of the West of England, Bristol, United Kingdom

  • Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton, United Kingdom

  • Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

  • Department of Haematology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke‐on‐Trent, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved